ArticleNature2025
Cell cycle duration determines oncogenic transformation capacity.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- KIF18A inhibitor prevents chromosomally unstable osteosarcoma growth by activating spindle assembly checkpoint.Cancer biology & therapy · 2026Article
- Article
- Real-World Evaluation of Next-Generation Sequencing in Lung Cancer: Associations Between Histological Subtypes and Genomic Alterations.Current issues in molecular biology · 2026Article
- KAS-CUT&Tag for direct mapping of transcription bubbles.bioRxiv : the preprint server for biology · 2026Article
- The role of methylation in pituitary neuroendocrine tumors current insights and emerging perspectives.Molecular biology reports · 2026Review
- Decoding clone evolution in HER2 amplified breast cancer through single-cell and spatial transcriptomics analysis of copy number variations.Scientific reports · 2026Article
- Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective.Biomarker research · 2026Review
- Low- and high-dose-rate radiation exposure alters the cellular composition and dynamics of the rat mammary epithelium for weeks preceding carcinogenesis.Journal of radiation research · 2026Article
- The Establishment of Prostate-specific, SKP2 Humanized Mice by CRISPR Knock-in Method Reveals Neoplastic Initiation and Microenvironmental Reprogramming.Research square · 2026Article
- Natural polysaccharides as multifunctional anti-cancer agents: structure-activity relationships, mechanisms of action, and therapeutic potential.Frontiers in immunology · 2026Review
- Cell-cycle-dependent repression of histone gene transcription by histone H4.Nature structural & molecular biology · 2026Article
- Identification of small GTPases as potential target proteins of the mycotoxin and renal carcinogen ochratoxin A.Archives of toxicology · 2026Article
- Impact of single-cell cell cycle regulation of intercellular communication on the prognosis of hepatocellular carcinoma in the tumor microenvironment.Clinical and experimental medicine · 2025Article
- FBXO5 drives hepatocellular carcinoma progression and is a target for tea polyphenol-mediated inhibition.Translational cancer research · 2025Article
- The Interplay Between Oxidant/Antioxidant System, Transcription Factors, and Non-Coding RNA in Lung Cancer.International journal of molecular sciences · 2025Review
- Centromeres drive and take a break.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2025Review
- Coupling of stemness maintenance with cell cycle control in stem cells.Frontiers in cell and developmental biology · 2025Review
- Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.Cancer heterogeneity and plasticity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Danian ChenLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.ORCID 0000-0002-6916-2978
Suying LuLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Katherine HuangLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.ORCID 0000-0003-0248-6078
Joel D PearsonLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Marek PacalLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Phillipos PeidisLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Sean McCurdyLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Tao YuLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Monika SangwanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
Angela NguyenLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.ORCID 0000-0002-7453-2232
Philippe P MonnierDepartment of Ophthalmology and Visual Science, University of Toronto, Toronto, Ontario, Canada.
Daniel SchramekLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.ORCID 0000-0001-9977-2104
Liang ZhuDepartment of Developmental and Molecular Biology, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0003-3789-2076
David SantamariaMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, Salamanca, Spain.
Mariano BarbacidMolecular Oncology Program, National Center for Cancer Research (CNIO), Madrid, Spain.
Nagako AkenoDivision of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Kathryn A Wikenheiser-BrokampThe Perinatal Institute Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Rod BremnerLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. bremner@lunenfeld.ca.ORCID 0000-0001-9184-7212
Funding
Role of Rb Family in Lung Epithelial Response to InjuryR01HL079193 · NHLBI · UNIVERSITY OF CINCINNATI · PI WIKENHEISER-BROKAMP, KATHRYN ANN · 2005 to 2013
$3.4MNHLBI NIH HHS R01 HL079193
Abstract
Oncogenic mutations are widespread in normal human tissues
Indexed as
Cell CycleCell Transformation, NeoplasticAnimalsApoptosisCDC2 Protein KinaseCell LineageCell ProliferationCellular SenescenceCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p27DNA RepairFemaleHumansImmunologic SurveillanceMaleMiceCDC2 Protein KinaseCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p27Proto-Oncogene Proteins p21(ras)Retinoblastoma-Like Protein p107Retinoblastoma ProteinS-Phase Kinase-Associated ProteinsTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.